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ABSTRACT 
AXON INITIAL SEGMENT STABILITY IN MULTIPLE SCLEROSIS 
By Suneel Krishna Thummala M.B.B.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master 
of Science at Virginia Commonwealth University.  
 
Virginia Commonwealth University, 2015.  
 
Thesis Advisor: Jeffrey L. Dupree, Ph.D.  
Associate Professor of Anatomy and Neurobiology  
 
 
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system 
characterized by inflammation and demyelination. In addition to these hallmark 
features, MS also presents with axonal pathology, which is likely responsible for the 
signs and symptoms of the disease. Although prominent in MS, axonal pathology is 
frequently considered a consequence of demyelination and not a primary event. 
This conclusion is consistent with demyelination inducing the loss of specific axonal 
domains, known as the nodes of Ranvier that are responsible for the propagation of 
action potentials along the axon.  In contrast, we propose that axonal pathology 
associated with MS is also independent of demyelination, and not a product of it. In 
support of our hypothesis, we have analyzed a different axonal domain known as 
the axon initial segment. Whereas a single axon has numerous nodes of Ranvier 
uniformly distributed along the axon, each axon contains only a single axon initial 
segment that is positioned immediately distal to the neuronal cell body. The axon 
initial segment is responsible for action potential generation and modulation, and 
 x 
hence is essential for normal neuronal function.  Background studies conducted by 
our lab, employing a murine model of demyelination/remyelination, revealed no 
correlation between axon initial segment stability and myelin integrity. Here we 
investigate the fate of the axon initial segment in human multiple sclerosis. While 
not statistically significant, we provide data demonstrating an apparent 40% 
reduction in AIS numbers in MS. These findings are, however, highly preliminary 
due to the limited number of samples. We further provide qualitative evidence that 
AIS disruption in MS is not dependent on demyelination suggestive that axonal 
pathology may be a primary event in MS. Our current findings are intriguing, but 
unfortunately this study is underpowered, and more samples will be required to 
determine whether this apparent reduction is statistically significant.  
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INTRODUCTION 
 
Multiple sclerosis is a pervasive, debilitating disease of the central nervous system.  
In the early 19th century, Charcot first described the ‘sclerotic plaques’ from which 
the disease eventually got its name (Charcot, 1868; as reviewed in Kornek and 
Lassmann, 1999). These plaques are the histopathological hallmark feature of this 
prototype demyelinating disease, characterized by the presence of well 
circumscribed, multifocal inflammatory demyelinated lesions distributed over time 
and space within the CNS (Files, 2015; Haines, 2012; Grigoriadisa, 2004). MS affects 
approximately 400,000 individuals in the United States and affects 2.5 million 
individuals worldwide (World Health Organization, 2008). Despite being clinically 
silent for a large portion of its process, MS eventually presents with non-specific 
cognitive symptoms such as sensory disturbances, ophthalmoplegia, parasthesias, 
neuralgias, ataxia and/or neurogenic bowel and bladder symptoms (Noseworthy, 
2000; Files, 2015). As the disease advances, patients undergo progressive cognitive 
and/or psychiatric decline, having life expectancies shortened by 5-10 years, 
attributable to increased risk of complications from neurological disability 
(Compston and Coles, 2008).  While studies have demonstrated a strong correlation 
between this progressive neurological impairment and neurodegenerative 
pathology, this process is traditionally considered to be a consequence of 
demyelination (Hauser and Oksenberg, 2006). It has recently been proposed that 
axonal pathology in MS could be a primary event in the disease process (Trapp et al., 
1998; Trapp and Nave, 2008; Haines et al., 2011). This project aims to explore this 
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concept, specifically investigating the susceptibility of a particular axonal domain, 
the axon initial segment (AIS) to the multiple sclerosis disease process.  
 
The Neuron: 
Neurons are the specialized cell types of the central and peripheral nervous 
systems. They are polarized cells, responsible for intercellular communication 
through electrical or chemical signaling within the nervous system and to target 
organs. Neurons are structurally and functionally composed of 3 distinct parts: the 
dendrites, the cell body and the axon. Together the dendrites and the cell body 
constitute the somatodendritic region. Dendrites are short membranous processes 
exhibiting a tapered morphology, responsible for the reception and integration of 
electrical and/or chemical synaptic inputs from neurons and other cells (Kevenaar 
and Hoogenrad, 2015). The axon is the thin, long projection from the neuronal cell 
body that transmits the signal to the receptors of subsequent neurons or other cells, 
in the form of an electrical wave called the action potential (Stiess and Bradke, 
2011). The axon is composed of specialized regions, such as: the axon hillock, axon 
initial segment, nodes of Ranvier and the axon terminal, each playing a vital role in 
this process.  The axon hillock bridges the soma and the axon, and is the site where 
inhibitory and excitatory synaptic inputs summate. The region adjacent to the axon 
hillock is the axon initial segment, a highly specialized domain, composed unique 
structural proteins and ion channels that allow for the generation and modulation of 
an action potential (Clark et al., 2009; Buffington and Rasband, 2011). The nodes  
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Figure 1. Schematic representation of a neuron.  The chief components of a 
typical CNS neuron highlighting the cell body (soma) and the axon, and their 
various subparts. An oligodendrocyte and its contributing myelin sheath are also 
observable. The axonal domains, the nodes of Ranvier and the axon initial 
segment are labelled.   
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of Ranvier (NoR) are short regions of the axon that lack a myelin sheath (the 
insulating membrane that wraps around the axon). Both the myelin sheath as well 
as the NoRs function in action potential propagation along the axon, ending in the 
axon terminal, where the impulse is transmitted to target cells/organs through the 
synapse, via electrical or chemical signals (Susuki and Rasband, 2008)  
 
Myelin: 
The term ‘myelin’, first coined by Rudolf Virchow in 1864, is used to describe the 
lipid dense extension of the plasma membrane of oligodendrocytes (in the CNS) and 
Schwann cells (in the PNS), which surrounds the axon, forming an insulating sheath 
(Raine, 1984; Snaidero and Simons, 2014; Boulanger and Messier, 2014; Alizadeh et 
al., 2015).  By insulating the axon, and clustering sodium channels into the nodes of 
Ranvier, myelin reduces the transverse capacitance and increases the transverse 
resistance of the axonal plasma membrane, crucial for saltatory nerve conduction, 
the basis of rapid information processing and communication between networks of 
nerve cells in the CNS (Aggarwal et al., 2011; Nave and Werner., 2014; Hartline and 
Colman, 2007). Oligodendrocytes, the myelin-forming cells of the CNS, extend their 
plasma membranes in concentric loops, each process contacting and enveloping a 
segment of the axon, forming a multi-layered sheath (Tomassy et al., 2015).  In 
addition to myelin generation, oligodendrocytes secrete metabolic factors that are 
essential for the survival and integrity of CNS neurons (Tomassy et al., 2015; 
Chamberlain et al., 2015; Edgar et al., 2009; Fünfschilling et al., 2012; Lee et al., 
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2012; Oluich et al., 2012). Maintenance and repair of the myelin sheath occurs 
throughout adult life and includes spontaneous remyelination of neurons by 
oligodendrocytes and their precursors (Irvine and Blakemore, 2008; Jeffery and 
Blakemore, 1997; Kornek et al., 2000).  
With an unusually high lipid concentration compared to other biological 
membranes, myelin is composed of 30% protein and 70% lipid, a configuration that 
is essential to myelin’s insulating property and function (Aggarwal et al., 2011) The 
abundance of cholesterol, which constitutes 24-28% of total myelin lipids, likely 
restricts membrane fluidity and carving affecting intercellular trafficking (Jahn et al., 
2009). Cholesterol is also the rate-limiting step in the formation of myelin, as 
demonstrated by experiments conducted using Zebrafish, lacking the enzyme for 
cholesterol synthesis (Mathews et al. 2014; Saher et al. 2005, 2009) Other lipids of 
note are galactolipids, galactosylceramide (GalC), its sulfated form 3-O-
sulfogalactosylceramide (SGalC), and their hydroxylated forms GalC-OH and SGalC-
OH, which together add up to 20–26% of total myelin lipids (Bosio et al., 1998). 
These lipids play crucial roles in interactions between the oligodendrocyte and the 
axon, as well as maintenance of myelination (Coetzee et al., 1996; Dupree et at., 
1998; Bosio et al., 1998). Plasmalogens are a class of phospholipids that make up 
12-15% of the total myelin lipid. Plasmalogens have an anti-oxidant effect, and 
decreased levels have been implicated in demyelination in X-linked 
adrenoleukodystrophy (Khan et al., 2008).  
Of the principal protein components of CNS myelin, proteolipid protein (PLP) 
and its smaller splice isoform, DM20, are the most prominent, making up 30-45% of 
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myelin protein. PLP plays a role in the formation of the intraperiod line, however, 
despite their abundance, these proteins do not appear to play a vital role in the 
establishment or maintenance of myelin, as studies using PLP/DM20 knockout mice 
revealed periodicity issues, but did not show wide spread demyelination (Klugmann 
et al., 1997; Coetzee et al., 1999) 
Myelin basic protein (MBP) is the second most abundant myelin protein, 
comprising up to 22–35% of total myelin protein. MBP plays a crucial role in myelin 
compaction and stabilizing the major dense line, and absence of MBP results in 
severe hypomyelination, as seen in the mouse mutant shiverer and the rat mutant 
long evans shaker  (Roach et al., 1985; O’Connor et al., 1999).  
Other proteins of interest include 2′:3′-Cyclic nucleotide-3′-
phosphodiesterase (CNP), myelin-associated glycoprotein (MAG) and myelin-
oligodendrocyte protein (MOG).  CNP is a major component of non-compact myelin, 
and is associated with oligodendrocyte processes and paranodal loops and is said to 
play a role in the cytoskeletal network of myelin (DeAngelis and Braun, 1996). MAG 
functions in facilitating adhesion and signaling, between oligodendrocytes and 
axons, during myelin formation (Quarles et al., 1992; Quarles and Morell, 1999). 
MOG functions in transmitting extracellular information to the interior of 
oligodendrocytes (Quarles et al., 2006). It is of particular interest to us because it is 
the antigen that, when injected into an animal, elicits a cellular immune response 
that produces the CNS autoimmune disease experimental autoimmune 
encephalomyelitis (EAE).  
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Axonal Domains: 
Myelinated axons show a high degree of structural and functional organization, and 
can be separated into several distinct, specialized domains; the node of Ranvier 
(NoR), the paranode, the juxtaparanode, the internode and the axon initial segment 
(AIS). These domains have similarities and differences with regards to structural 
protein composition, function, and mechanisms of establishment and maintenance. 
While they each play important roles in proper neuronal functioning, for the 
purposes of this thesis, we will focus on the node of Ranvier and the axon initial 
segment. 
 
Nodes of Ranvier: 
The nodes of Ranvier are myelin-bare regions of the axon spanning approximately 
1- 2 μm in length (Peters et al., 1991; Salzer, 1997). The constricted diameter of the 
node of Ranvier results in slowed axonal transport and therefore, higher densities of 
vesicles, microtubules, mitochondria, and tightly packed neurofilaments (Fabricius 
et al., 1993; Peters et al., 1991; Salzer, 1997). Vital for its role in action potential 
propagation, the node contains a high concentration of voltage gated sodium 
channels (Nav), including isotypes; Nav 1.1, Nav 1.2 and Nav 1.6 (Arancibia‐
Carcamo and Attwell, 2014; Buttermore et al., 2013; Thaxton and Bhat, 2009; Salzer, 
1997). These sodium channels are anchored to the cytoskeleton through interaction, 
at either its α- or β- subunits, with the scaffolding protein ankyrinG (ankG) (Bennett 
and Lambert, 1999; Buttermore et al., 2013; Thaxton and Bhat, 2009). AnkG 
associates with the spectrin- actin cytoskeleton through interactions with βIV-
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spectrin, which is exclusively localized in the node and axon initial segment (Berghs 
et al. 2000; Buttermore et al., 2013; Komada and Soriano, 2002). The node of 
Ranvier also contains extracellular matrix molecules, cell adhesion molecules and 
certain types of potassium channels. 
Saltatory conduction is the process by which action potentials ‘jump’ across 
unexcitable portions of the axon (myelin segments) from one node to the next. This 
process is made possible by the high density clustering of sodium channels at the 
nodes of Ranvier where ion flow occurs exclusively after the impulse has left the AIS 
(Salzer, 2003; Sherman and Brophy, 2005). Ion channel clustering, as well as its 
interactions with the ankyrinG and βIV-spectrin/actin network, at the node of 
Ranvier is, therefore, vital for efficient action potential transmission (Bennett and 
Lambert, 1999; Buttermore et al., 2013; Thaxton and Bhat, 2009). AnkyrinG, 
described as the master regulator of AIS and NoR assembly (He et al., 2013; Kordeli 
et al., 1995; Jenkins and Bennett, 2001; Sobotzik et al., 2009; Hedstrom et al., 2008; 
Dzhashiashvili et al., 2007; Zhou et al. 1998), is responsible for the clustering of Nav 
channels at the NoR.  Sodium channels are anchored to the actin-cytoskeleton 
through direct interaction with the scaffolding protein ankyrinG and indirect 
interaction through adapter protein βIV-spectrin (Rasband, 2010; Eshed-Eisenbach 
and Peles, 2013). Establishment of these interactions is critical for nodal clustering, 
as mice lacking these stabilizing cytoskeletal associated proteins (ankG and/or βIV-
spectrin) display severely reduced sodium channel density (Gasser et al., 2012; 
Komada and Soriano, 2002; Yang et al., 2004). Additionally, not only is ankyrinG 
required for the establishment of the node of Ranvier, but it is also critical for 
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maintaining the nodal protein complexes; as knock down of ankG results in cluster 
dismantling (Hedstrom et al., 2008).  
While myelin contact at the paranode is required for node of Ranvier 
formation it is also vital for nodal maintenance. Studies conducted by our lab and 
others show that compromised myelin-axon interactions result in a disruption of 
nodal protein domain organization (Eshed-Eisenbach and Peles, 2013; Susuki et al., 
2013; Dupree et al., 1999). The Cuprizone model (discussed in detail later) is a 
demyelinating murine model, in which myelin-forming oligodendrocytes are killed, 
resulting in a complete loss of both nodally clustered sodium channels, as well as 
paranodal clusters of caspr (Dupree et al., 2004).  
 
Axon Initial Segment: 
The axon initial segment (AIS) is an unmyelinated region of the axon, spanning 
about 35-45 μm distally from the soma, located between the axon hillock and the 
first myelin segment, in myelinated neurons. (Bender and Trussell, 2012; Grubb and 
Burone, 2010; Rasband, 2010). The AIS serves as the site for action potential 
initiation and modulation, as well as a gatekeeper between the somatodendritic and 
axonal domains (Meeks et al., 2007; Rasband, 2010). Because the AIS and the node 
of Ranvier both play roles in action potential transmission, their protein clusters are 
very similar in composition (Rasband, 2010).  
The axon initial segment serves as the action potential trigger zone due to its 
high density of voltage-gated sodium channels. The AIS integrates signals from the 
somatodendritic region of the neuron, and acts as an action potential threshold 
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“decision maker” (Inan et al., 2013; Kole and Stuart, 2012; Tai et al., 2014; 
Yosihmura and Rasband, 2014). Action potential amplitude, duration and frequency 
are thought to be regulated by the diversity of potassium channel subtypes (Kv1.2, 
Kv2.2 and Kv7.2) present in the AIS (Kole et al., 2007; Sánchez-Ponce et al., 2012). 
The AIS also undergoes frequent plasticity, such as changes in ion channel 
localization and expression, alterations in AIS length, and physical relocation of the 
AIS; all due, in part to synaptic input and pruning; thus fine-tuning neuronal 
excitability (Adachi et al., 2014; Grubb and Burrone; Kaphzan et al., 2011; Kuba et 
al., 2010,2012).  
In addition to its role in action potential initiation and modulation, the axon 
initial segment serves as a barrier between the somatodendritic and axonal 
domains; thus maintaining neuronal polarity (Rasband, 2010). The mechanism 
underlying this barrier is not fully understood, but it is hypothesized that the vast 
number of AIS proteins could act as a sieve to weed out larger cytoplasmic 
molecules (Nakada et al., 2003; Rasband, 2010).  
The axon initial segment, like the node, contains a high density of voltage 
gated sodium channels (Nav 1.1, Nav 1.2 and Nav 1.6); about 40-50 times that of the 
somatodendritic domains (Rasband, 2010; Kole et al., 2008). Unlike the node, which  
assists in the propagation of action potentials, these AIS Na+ channel clusters serve 
as the trigger zone (Meeks et al., 2007). Similar to the node, the AIS is composed of a 
variety of ion channels, cell adhesion molecules, extracellular matrix molecules and 
cytoskeletal scaffolds. The master organizer molecule ankyrinG is responsible for 
the interaction of these sodium channels to the axonal cytoskeleton and  
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Figure 2. Axon initial segment and its constituent proteins. Ion channels, cell 
adhesion molecules, neurotransmitter receptors and cytoskeletal proteins are 
enriched at the AIS. AnkyrinG, dubbed the ‘master organizer’ of the AIS binds β4 
spectrin and Nav channels.  
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maintenance of neuronal polarity. Additionally, ankG silencing and its removal from 
the mature AIS results in dismantling of the AIS, as detected through dispersion of 
sodium channel, βIV-spectrin, NF-186, and NrCAM immunolabeling (Hedstrom et al., 
2008). AnkG is therefore, not only required for the initial recruitment and clustering 
of AIS proteins, but also for the long-term maintenance of this domain. Recently, the 
first human mutations in ankG were reported and shown to be associated with 
severe intellectual disability, attention deficit hyperactivity disorder, and autism 
(Iqbal et al., 2013).  
Although the node of Ranvier and the AIS contain very similar protein 
clusters, they are established and maintained through different processes, the most 
noteworthy being their relationship with myelin. While both the formation and 
maintenance of the node of Ranvier requires myelin contact, the AIS is formed 
intrinsically through ankG restriction to the proximal end of the developing axon, 
completely independent of myelination (Bennett and Baines, 2001; Galiano et al., 
2012). Data regarding the maintenance of the AIS with relation to myelin, is 
however limited. Preliminary studies show that myelin may not be required to 
preserve AIS integrity (Clark et al., [in review]; Hamada and Kole, 2015).  
 
Multiple Sclerosis: 
Multiple sclerosis (MS) is a debilitating neurological disease, characterized by the 
immune mediated destruction of the myelin sheath, with subsequent neurological 
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damage (Compston and Coles, 2002). MS is the leading cause of neurological 
disability in young adults, and currently affects over 400,000 people in the United 
States, and over 2.5 million people worldwide (Hauser and Oksenberg, 2006; 
Noseworthy, 1999; Noseworthy et al., 2000; Trapp and Nave, 2008; Weinshenker, 
1998). MS shows a peculiar worldwide distribution, with increased prevalence in 
populations progressively further away from the equator. MS also 
disproportionately affects females more than males, at a ratio of ~3:1 (Ahlgren et al. 
2011; Compston and Coles, 2002; Orton et al. 2010; Wallin et al. 2012). MS is a 
highly variable disease, believed to arise from a combination of genetic interactions 
and environmental influences, but little is truly known about its cause or the factors 
contributing to its unpredictable course and outcome (Compston and Coles, 2008) 
Multiple sclerosis may follow one of four clinical courses based on disease activity 
and progression: clinically isolated syndrome (CIS), relapsing-remitting multiple 
sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), and secondary 
progressive multiple sclerosis (SPMS) (Lublin et al., 2014).  
Clinically isolated syndrome (CIS) presents as a single isolated attack, 
characterized by symptoms compatible with MS, but has yet to fulfill MS diagnostic 
criteria. These patients may or may not progress to full blown MS (Miller et al., 
2012). Approximately 85 to 90 percent of affected adults develop relapsing-
remitting multiple sclerosis (RRMS) at onset, with a clinical course characterized by 
intermittent attacks of increased disability followed by either partial or complete 
recovery to their baseline function (Simone et al., 2002; Gusev et al., 2002; Banwell 
et al., 2007; Renoux et al., 2007; Boiko et al., 2002). RRMS may evolve to secondary 
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progressive multiple sclerosis (SPMS) in individuals who eventually show 
progressive neurological decline without acute attacks or periods of remission. 
Primary progressive multiple sclerosis (PPMS), a disease type characterized by 
continuous disability over time in the absence of specific attacks, is much less 
common than RRMS. A PPMS course is associated with the most rapid disease 
progression and has the poorest prognostic value (Weinshenker, 1994; Tremlett et 
at., 2006).  
 
Pathogenesis:  
Multiple sclerosis is thought to be attributable to an autoreactive attack on myelin 
and oligodendrocytes by cells of the immune system that have entered the brain 
and/or spinal cord, manifesting as acute focal inflammatory demyelination and 
axonal loss with limited remyelination, culminating in the chronic multifocal 
sclerotic plaques from which the disease gets its name. (Trapp and Nave, 2008) To 
better understand the characteristic pathology of MS, we will tease apart and 
examine each aspect individually.   
 
MS Inflammation: 
Inflammation in MS is believed to be mediated by a coordinated attack by T 
lymphocytes and macrophages, against CNS tissue (Boppana et al., 2011). T cells 
cross the blood brain barrier to enter the CNS. Activation of autoimmune responses 
against myelin components in the CNS is hypothesized to occur through a variety of 
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mechanisms such as molecular mimicry, bystander activation and epitope spreading 
(Trapp and Nave, 2008; Popescu and Lucchinetti, 2012; Vanderlugt and Miller, 
2002; von Herrath et al., 2003). As lymphocytes secrete matrix metalloproteinases 
(MMP) to break down the blood brain barrier (BBB), the activated, autoreactive T 
lymphocytes in the periphery, attach themselves to the receptors of endothelial 
cells, granting them access through the BBB and into the central nervous system 
(Compston and Coles, 2002, Hauser and Oksenberg, 2006).  Once inside CNS 
parenchyma, the T cells, reactivated by CNS myelin, stimulate pro-inflammatory 
cytokines, such as TNF- α (Peterson and Fujinami, 2007; Hauser and Oksenberg, 
2006), which stimulate the resident microglia and recruit B cells, astrocytes and 
macrophages. Microglia secrete a host of factors such as TNFα (Haji et al., 2012), 
iNOS (Starossom et al., 2012), IL-1β, COX2 and generate reactive oxygen species 
(Guemez-Gamboa et al., 2011; Block et al., 2007) setting up a pro-inflammatory 
loop. This combination of events creates an environment in which the hallmark 
pathological processes of multiple sclerosis: demyelination and neuronal damage, 
occur.  
 
MS Demyelination: 
The pathologic hallmark of MS consists of areas of focal demyelination, known as 
plaques, characterized by reactive glial scar formation, inflammation, and partial 
axonal sparing (Kutzelnigg and Lassmann, 2014). Both humoral and cell mediated 
immune mechanisms play roles in the formation of these demyelinated lesions. As 
described earlier, autoreactive T cells are responsible for the propagation of a highly 
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inflammatory environment, bind to MHC class I antigens on oligodendrocytes to 
cause cell injury or they may produce demyelination through the endogenous 
production of inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and 
interferon-γ (INF-γ) (Noseworthy, 1999). Additionally, T cells drive the activation 
and recruitment of microglia and macrophages, both key players in the initial and 
sustained immune response to myelin antigens. Apart from secreting a variety of 
cytotoxic and inflammatory factors, microglia can directly contact the myelin sheath 
and oligodendrocytes, delivering lethal signals through surface bound TNFα (Zajicek 
et al., 1992; Compston and Coles, 2002).  
B cell activation and production of antibodies play a critical role in the 
development of demyelination.  Antibodies to myelin antigens such as myelin basic 
protein (MBP) and myelin oligodendrocyte protein (MOG) have been detected in MS 
plaques (Genain et al., 1999; O'Connor et al., 2005; O’Connor et al., 2007). Studies 
show that novel targets to non-myelin antigens such as KIR4.1, neurofascin and 
SPAG-16 mediate demyelination and axonal disruption (Fraussen et al., 2014; Levin 
et al., 2013).   
Demyelinated plaques in MS can be observed in both the white matter, as 
well as cortical and subcortical gray matter (Brück 2005; Calabrese 2015). Plaques 
are graded based on macrophage activity within the lesion. Acute active plaques are 
characterized by massive infiltration of myelin-laden macrophages, with relative 
axonal preservation and variable loss of oligodendrocytes (Brück et al., 1995; 
Kutzelnigg and Lassmann, 2014; Popescu and Lucchinetti, 2012). Other 
demyelinated lesions of interest are, chronic active plaques: regions of peripheral 
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macrophage activity with hypocellular, gliotic centers; inactive plaques: completely 
demyelinated, hypocellular lesions; and shadow plaques: sharply circumscribed, 
light myelin staining regions representing areas of partial remyelination (Popescu 
and Lucchinetti, 2012; Sobel and Moore, 2008; Prineas et al., 2001; Lucchinetti and 
Bruck, 2004).  
 
MS Neurodegeneration: 
While multiple sclerosis has historically been considered a prototype demyelinating 
disease, neuronal pathology plays an integral role in the functional pathogenesis of 
MS. Charcot’s findings, describing substantial axonal damage in active lesions 
(Kornek and Lassmann, 1999), were largely ignored until more recent landmark 
papers revealed abundant transected and dystrophic axons in sites of active 
inflammation and demyelination, and confirmed that partial or total axonal 
transection begins early in the disease process (Bitsch et al., 2000, Ferguson et al., 
1997 and Trapp et al., 1998).  Various pathological studies have demonstrated 
reduced axonal density and in active, chronic and inactive plaques (DeLuca et al., 
2004; Bjartmar et al., 2000; Bitsch et al., 2000; Frischer et al., 2009). Accumulation 
of amyloid precursor protein (APP) within the axon is caused by disruption of APP 
transport down the axon, and is evidence of compromised axonal structure 
integrity. APP accumulations have been observed in MS, within active lesions and 
chronic plaques (Lovas et al., 2000; Mews et al., 1998; Ferguson et al., 1997). Axonal 
pathology is further evidenced by magnetic resonance imaging (MRI) techniques, 
visualizing whole brain atrophy (Miller et al., 2002), worsening focal (T1) lesions 
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(Bagnato et al., 2003), disruption of white matter tracts, and altered functional 
connectivity by functional MRI (Cader et al., 2006). 
The mechanisms driving neuronal pathology in MS are of particular 
importance, as there appears to be a correlation between cumulative axonal loss 
and progressive, irreversible neurological disability (Neumann, 2003; Matthews et 
al., 1998; Paolillo et al., 2000; Fisher et al., 2000; Grimaud et al., 1999). As with 
demyelination, neuroaxonal damage in MS is a multifactorial process.  
We are yet to fully understand the mechanisms driving axonal pathology in 
MS. A correlation between demyelination and axonal loss has been demonstrated by 
numerous studies. Progressive axonal degeneration and disability was observed in 
murine models lacking either myelin associated glycoprotein (MAG) or proteolipid 
protein (PLP) (Li et al., 1994; Griffiths et al., 1998).  Similar findings were observed 
in humans carrying a null mutation in the gene encoding PLP1 (Garbern et al., 
2002). Histopathology of post mortem human MS tissue has shown axonal 
transections in lesions of active inflammation (Kornek et al., 2000; Trapp et al., 
1998). Furthermore we know that the establishment and maintenance of axonal 
domains is dependent on myelination (Dupree et al., 1999; Dupree et al., 2004; 
Marcus et al., 2006; Pomicter et al., 2010). 
The hypothesis that axonal damage in MS may occur independently of 
demyelination has been suggested by several studies and is a focus of this project. 
Axon-specific antibodies have been implicated in axonal degeneration (Zhang et al., 
2005). Axonal damage has also been linked to the presence of reactive resident 
microglia, invading inflammatory immune cells, and their toxic metabolites. Release 
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of reactive oxygen species, specifically NO, by immune cells has been demonstrated 
to directly damage axons and mediate the development of neurological symptoms 
(Acar et al., 2003 and Smith, 2005). Studies using post mortem cortical tissue in MS 
patients, described axonal abnormalities in areas devoid of demyelination, termed 
normal appearing white matter (NAWM) (Siffrin et al., 2010; Ramió-Torrentà et al., 
2006; De Stefano et al., 2003; Davies et al., 2004). The marked reduction of the 
neuron-specific marker N-acetyl aspartic acid in MS lesions, and normal appearing 
white matter (NAWM) in MS patients suggests that neuronal pathology can occur 
early in disease and prior to the formation of overt lesions (Siffrin et al., 2010). MRI 
studies on progressive brain atrophy have yet to prove that neuronal damage is 
secondary to demyelination (Rudick, et al., 1999; Miller et al., 2002; Narayan et al., 
1997). Siffrin et al., in 2010, showed that cortical demyelination occurred in the late 
stages of the disease, and believed it to be a consequence rather than a cause, of 
neuronal loss (Siffrin et al., 2010).  Thus axonal destabilization and damage has been 
shown to occur even in the absence of morphological evidence of demyelination, 
however, the mechanisms underlying this process as to how or where this damage 
precisely occurs, are still not entirely clear. We believe that investigating the 
stability of axonal domains, specifically the axon initial segment, could provide 
insight into the mechanisms regulating axonal degeneration and its relationship to 
myelination, in multiple sclerosis.  
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Background Data: 
As more and more studies are establishing that axonal pathology independent of 
myelin loss is a viable explanation of the pathogenesis of multiple sclerosis, our lab 
decided to investigate the behavior of the axonal domain, the axon initial segment 
(AIS), under similar circumstances. To first address this, we employed murine 
models of multiple sclerosis. 
 
EAE model: 
To evaluate AIS integrity in an inflammatory environment, we utilized the murine 
model of chronic experimental autoimmune encephalomyelitis (EAE) as previously 
described (DeVries et al., 2012; Secor McVoy et al., 2015; Dupree et al., 2015).  EAE 
is a murine model, which shares the inflammatory features of MS but none of the 
demyelinating aspects. 12 week old mice were injected with a cocktail consisting of 
myelin oligodendrocyte protein (MOG), Freund’s adjuvant containing heat-killed M. 
tuberculosis and Pertussis toxin (PT). This induced an inflammatory CNS response, 
producing clinical symptoms as early as 5 days post-induction. Clinical motor 
symptoms were scored daily following immunization and were recorded as follows: 
0= no signs, 1.0= limp tail, 2.0= loss of righting reflex, 3.0= paralysis of single hind 
limb and 4.0= paralysis of both hind limbs. Mice achieved peak clinical symptoms at 
~15 days post induction. Two experimental time points were established: an early 
inflammatory time point (3 days post peak clinical symptoms) and a late 
inflammatory time point (9 days post peak clinical symptoms). Not all mice achieved 
maximum clinical scores by day 10, allowing us to exploit this variation to 
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investigate the correlation between disease severity and extent of axonal pathology. 
Within each time point, mice were categorized as either EAE 1&2, or EAE 3&4 based 
on clinical scoring.  
 
Axon initial segments were shortened following early EAE: 
Immunolabeling for markers directed against ankyrinG allowed visualization of 
axon initial segments (AIS) in cortical layer V of mice. Quantitative analysis of AIS 
numbers and length in layer V or the cortex of EAE mice at the early inflammatory 
time point revealed no change in AIS numbers among any of the groups. No change 
in AIS length was observed between naïve and early EAE 1&2, however early EAE 
3&4 mice showed significantly shortened mean AIS lengths, compared to both the 
naïve and EAE 1&2 groups. To determine whether this shortening was an early 
event in progressive AIS disruption, or whether the shortening would 
spontaneously correct itself with disease progression, we quantified AIS numbers 
and lengths at the late inflammatory EAE time point.  
 
Axon initial segments were lost during late EAE:  
AIS morphology was assessed following 9 days post peak clinical symptoms (late 
EAE). In contrast to the mice at early EAE, quantification of AISs at the late EAE 
stage revealed significantly reduced numbers of AIS in both EAE 1&2 and EAE 3&4 
groups compared to the naïve mice. As seen in Figure 3 approximately 60% of AISs 
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Figure 3. AIS length is reduced in early stages of EAE while the number of AISs 
is decreased in the late stages of disease. In Early disease stage (3 days post peak 
clinical symptoms), AISs in cortical layer V neurons of naïve (A) and EAE 1&2 (B) 
mice were abundant, presented with uniform length and rarely revealed 
discontinuous labeling indicative of fragmentation (yellow arrows).  In contrast, 
AISs of layer V cortical neurons in Early EAE 3&4 mice (C) were frequently reduced 
in length (white arrows) and fragmented (yellow arrows). Quantitative analysis 
confirmed the immunohistochemical observations. No difference in AIS number 
was observed among the Early EAE groups (G). Although no difference in AIS length 
was observed between naïve and Early EAE 1&2 mice (H), a significant shortening 
was observed with the Early EAE 3&4 mice compared to naïve animals (H). In 
contrast, the Late EAE 1&2 mice (E,G) exhibited a significantly reduced in the 
number of AISs with a continued progression in AIS loss observed in the Late EAE  
3&4 mice (F,G).  While there was a significant decrease in AIS length for the Late 
EAE 1&2 mice, a significant but less dramatic shortening was observed for the Late 
EAE 3&4 mice as compared to the naïve animals (H). Note that with the loss of AISs 
(Panel F), punctate AnkG labeling was prevalent. Double labeling for AnkG and the 
paranodal marker caspr (see F inset; AnkG – red; caspr – green) revealed that these 
pucta were nodes of Ranvier that were not disrupted following EAE induction.  
(Asterisks with no associated bracket represent a significant difference from the 
naïve group; *p=0.0001, **p=0.008). 
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were lost in the late EAE 1&2 while nearly 75% of AISs were lost in the late EAE 3&4 
mice. AIS lengths were measured at the late inflammatory time point as well, 
revealing significantly shorter AIS lengths in both EAE 1&2 and EAE 3&4 groups 
compared to the naïve mice.  
Therefore, we show that the AIS are significantly shortened and the number 
significantly reduced in EAE mice. These findings are extremely exciting as they 
show a disruption of axonal protein domain organization in the absence 
demyelination.  
 
Cuprizone Model: 
Demyelination does not disrupt molecular organization of the AIS:  
Although MBP labeling detected no demyelination in the cortex of the EAE mice, 
subtle, undetected disruptions between the myelin sheath and axon could be 
responsible for the loss of AIS protein clustering. To determine whether disrupted 
axon-myelin interaction could compromise AIS protein clustering, we analyzed AIS 
length and number following demyelination of the cortex using the curizone model. 
Exposure of the neurotoxicant, cuprizone (bis-cyclohexanone-oxaldihydrazone), to 
young adult C57BL/6 mice induces a synchronous and consistent model for 
demyelination followed by remyelination of the 5th layer of the cerebral cortex 
(Mason et al., 2001; Matsushima and Morell, 2001; Skripuletz et al., 2008)  
6-week-old mice were fed ground chow mixed with cuprizone following a 
previously described protocol (Hiremath et al., 1998; Dupree et al., 2004). Treated 
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animals were removed from cuprizone after 3 or 5 weeks for tissue processing and 
analysis, while an additional group was maintained on cuprizone for 5 weeks 
followed by an additional 3 weeks on normal (non-cuprizone) chow.  
 
Cuprizone induced demyelination does not disrupt AIS structure: 
A qualitative assessment of myelin basic protein (MBP) immunolabeling of cortical 
layer V, to assess for myelination, revealed reduced MBP levels in mice following 3 
weeks of curizone exposure. Following 5 weeks of cuprizone exposure, MBP levels 
were further reduced, indicating maximum demyelination. MBP labeling of mice 
following the additional 3 weeks of normal chow after 5 weeks cuprizone exposure 
revealed an increase in MBP labeling which is consistent with remyelination of 
cortical layer V.  
Immunolabeling for markers directed against ankyrinG allowed us to 
visualize the axon initial segments in cortical layer V of cuprizone mice. Quantitative 
analysis of AIS numbers across 3-week-old, 5-week-old cuprizone mice and 5+3 
week old cuprizone + normal chow mice revealed no disruption to the organization 
of AISs following demyelination. Interestingly, nodes of Ranvier cluster a similar set 
of proteins as the AIS, yet following demyelination, these proteins, including Na+ 
channels and ankyrinG, are no longer clustered in the node of Ranvier. In contrast, 
our AIS findings show that following demyelination these proteins maintain their 
clustering suggesting that these proteins have differential susceptibility to 
pathologic events depending on their location along the axon. 
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In summary, our findings demonstrate that the AIS is compromised in EAE, and this 
structural disruption is independent of demyelination. 
Although these findings are highly intriguing by indicating that axonal pathology 
may be independent of myelin loss in an inflammatory environment, these data are 
limited to animal models. Here, we will investigate whether similar AIS structural 
disruption occurs in human MS tissue. 
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Figure 4. AISs are not disrupted following cuprizone-induced demyelination. 
Cortical demyelination was assessed by immunolabeling for MBP (A-E). No myelin 
loss was detected following 1 week of cuprizone treatment (B). Note a slight 
reduction in MBP labeling following 3 weeks of cuprizone exposure (compare A 
and C) with a continued decrease in labeling by 5 weeks of treatment (D). 
Following an additional 3 weeks without cuprizone, MBP labeling increased 
consistent with remyelination (E). Ankyrin-G labeling of cortical layer V axon 
initial segments (AIS) revealed no difference among mice that were maintained on 
ground chow without cuprizone (F) and mice maintained on cuprizone for 1 week 
(G), 3 weeks (H), 5 weeks (I), or 5 weeks with an additional 3 weeks of recovery 
(J). Quantitative analysis confirmed that neither AIS number (K) nor AIS length (L) 
was altered following cortical demyelination at any exposure time point or as 
compared to untreated (naïve) mice. 
 30 
 
 
 
   
 
Figure 4 
 31 
 
MATERIALS AND METHODS 
 
 
Tissue: 
Unfixed cortical samples from multiple sclerosis (MS) and non- multiple sclerosis 
(MS) brains were obtained from the Rocky Mountain Multiple Sclerosis Brain Bank 
Center. The samples were stored in a freezer at -80°C. The sample information 
included patient age, sex, sample type, hours between death and tissue harvest, and 
post-mortem pathological evaluation (Table 1). The samples were inspected at VCU 
by a neurologist (Unsong Oh, M.D.) and pathologist (Christine Fuller, M.D.) and 
samples identified to be gray matter were collected. One 20mm x 15mm x 3mm 
specimen of gray matter from each sample was dissected and stored in a 25mm x 
20mm x 5mm Tissue-Tek® Cryomold® (Sakura Finetek USA. Torrance, CA) standard, 
and frozen in Optimal Cutting Temperature (OCT) compound (Sakura Finetek USA, 
Torrance, CA), to be used for immunocytochemistry. Another 20mm x 20mm x 5 
mm specimen of gray matter from each sample was collected and processed for 
western blot analysis.   
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Table 1. Donor information for the Rocky Mountain Multiple Sclerosis Centre brain samples used in this study 
 
 
 
Disease 
Summary 
Sample 
Number Age Gender HTTC Pathological Evaluation of the Brain 
MS 299 51 M - Widespread, chronic, inactive plaques 
MS 192 81 F 3 - 
MS 307 61 F - Extensive, remote, chronic, inactive plaques 
Control 352 75 F 4.75 Normal cellularity with minimal edema 
MS 324 66 F 2.5 Widespread and coalescent demyelinative plaques 
MS 344 64 F 5.5 Well demarcated, chronic plaques with cerebral atrophy 
Control 486 64 M 13.5 Normal cellularity 
Control 102 21 M 65.5 Bilateral hemorrhagic infarcts in pareitooccipital regions 
MS 438 75 F 19.5 
Massive periventricular plaque burden with corpus callosum 
atrophy 
MS 441 61 F - 
Marked cerebral atrophy with massive plaque burden in 
periventricular regions 
MS 436 - - - - 
MS 448 - - - - 
Control 101 - - - - 
Control 100 - - - - 
MS = multiple sclerosis; HTTC = hours to tissue collection; - = data not available (NA)  
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Immunocytochemistry: 
Antibodies: 
The mouse monoclonal antibody directed against ankyrinG (ankG) (NeuroMab, 
Davis, CA; N106/36; dilution of 1:200), and mouse monoclonal antibody directed 
against neurofascin (Nfasc) (NeuroMab, Davis, CA; L11A/41; dilution of 1:1000) 
were used to label the axon initial segments. Microglia were labeled with a mouse 
monoclonal antibody directed against CD 45 (AbD Serotec, Raleigh, NC; dilution of 
1:500), a rabbit polyclonal antibody directed against the ionized calcium binding 
adaptor molecule 1 (IBA-1) (Wako Chemicals USA, Richmond, VA; 1:1000), or a 
mouse monoclonal antibody human leukocyte antigen DR (HLA DR) (Dako, Ely, UK; 
dilution of 1:1000). Myelination of cortical tissue was visualized using a mouse 
monoclonal antibody directed against 2',3'-cyclic-nucleotide 3'-phosphodiesterase 
(CNP) (Covance, San Diego, CA; SMI 91R, dilution of 1:1000), and mouse monoclonal 
antibody directed against myelin basic protein (MBP) (Covance, Chantilly, VA; 
dilution of 1:1000). Mouse monoclonal antibody directed against ankyrinG (ankG) 
(generous gift from Dr. Manzoor Bhat, University of Texas - San Antonio Health 
Science Center) was used for western blotting. All secondary antibodies were 
fluorescently tagged with fluorochromes with excitation wavelengths of 405nm, 
488nm or 594nm obtained from Invitrogen Life Technologies (Grand Island, NY; 
AlexaTM Fluor) and used at a dilution of 1:500. 
 
 34 
Number of Samples: 
The number of MS and non-MS samples used for ankyrinG and IBA-1 
immunocytochemistry is as follows: MS (n=9), non-MS (n=4). The number of 
samples used for CNP immunocytochemistry is as follows: MS (n=4), non-MS (n=4). 
The number of samples used for CD45 immunocytochemistry is as follows: MS 
(n=9), non-MS (n=3). The number of samples used for MBP immunocytochemistry is 
as follows: MS (n=4), non-MS (n=3). The number of samples used for HLA-DR, Nfasc, 
and CD 68 immunocytochemistry is as follows: MS (n=2), non-MS (n=2). 
 
Tissue Processing: 
Gray matter samples of MS and non-MS tissue were frozen in OCT freezing 
compound and placed in a Leica CM 1850 UV cryostat for sectioning. The samples 
were placed on the cutting block, with the desired side facing upwards. 40μm 
thickness sections (10 sections per sample) were sectioned and mounted on 
ProbeOnTM Plus microscope slides (Fisher Scientific, Waltham, MA), one section per 
slide. The slides were labeled and stored in a freezer at -80°C.  
 
Immunofluorescent labeling: 
Sections were removed from the -80C freezer, and air-dried for 30 minutes to 
ensure adhesion to the slide during subsequent steps. Excess OCT was trimmed 
from the periphery of the slide and a PAP pen (Daido Sangyo, Tokyo, Japan) was 
used to apply a hydrophobic border around the tissue. For labeling with IBA-1, MBP 
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and Nfasc primary antibodies, the slides were immersed in 4% paraformaldehyde 
for 1 hour to fix the tissue. Slides were then immersed in -20°C acetone (Fisher 
Scientific; Pittsburg, PA) for 10 minutes, washed 3 times in phosphate-buffered 
saline (PBS) (0.1 M, pH 7.4; 8g of NaCl + 0.2g of KCl + 1.44g of Na2HPO4 + 0.24g of 
KH2PO4) and blocked in a solution of PBS, 0.5% Triton X-100 (MP Biomedicals; 
Solon, OH) and 10% cold water fish gelatin (Electron Microscopy Services; Hatfield, 
PA) for 15 minutes at room temperature.  The blocking solution was slightly 
modified for MBP labeling as 1% Triton X-100 was used instead of the routine 0.5% 
concentration. Sections were incubated overnight at 4°C in the appropriate primary 
antibodies diluted in the blocking solution. One the following day, the sections were 
rinsed 3 times in PBS, blocked for 15 minutes at room temperature and incubated in 
the appropriate fluorescently labeled secondary antibody, which is dependent on 
the host species of the primary antibody. Secondary antibodies were diluted 1:500 
in the blocking solution and applied to the sections for 90 minutes. Following the 
secondary antibody incubation, sections were rinsed 3 times in PBS, incubated in 
BisBenzimide (Sigma-Aldrich, St. Louis, MO, 1:1000 for 2 minutes diluted in PBS) to 
label nuclei, rinsed 3 times in PBS and mounted with a coverslip (Fisher Scientific, 
Waltham, MA) using the antifade solution VectaShield™ (Vector Laboratories; 
Bulingame, CA),  and stored at -20°C until imaged. Images not imaged within 1 week 
of staining were stored in a freezer at -80°C.  
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Confocal Microscopy Imaging: 
Samples were first visualized using a Zeiss AxioImager A1 fluorescence microscope 
(Carl Zeiss Microscopy, LLC, Thornwood, NY) to ensure that the 
immunocytochemistry was effective and to confirm correct orientation of the 
sections. All images for qualitative and quantitative analyses were taken with a Zeiss 
LSM 710 confocal laser-scanning microscope (Carl Zeiss Microscopy, LLC, 
Thornwood, NY). Images were collected and compiled as maximum projection z 
stack images consisting of 50 optical images spanning 25μm of tissue. The collection 
of 50 images was determined based on Nyquist sampling, 1 Airy disc unit pinhole, 
using a 40x oil immersion objective with a numerical aperture of 1.3 Images were 
captured at 1908x1908 pixels using a scan average of 2. Each microscopic field 
dimension was 215µm x 215µm x 25 μm and each field of view (FOV) collected had 
a negligible area without tissue present. Gray matter regions were initially 
confirmed based on cell density and pattern of lipofuscin labeling. Non-overlapping 
images were taken only from gray matter regions. Between 4-6 images were 
collected per section. For 405nm excitation, wavelengths between 440-470 were 
collected. For 488nm excitation, wavelengths between 505-530 nm were collected.  
For 594nm excitation, wavelengths between 610-650 nm were collected.   
Spectral unmixing is a technique used to separate and omit autofluorescent 
wavelengths originating from lipofuscin pigment from the fluorescent wavelengths 
of interest originating from the antibody tags (Figure 5). Autofluorescence 
elimination facilitated quantitative analysis by removing non-specific fluorescence. 
Spectral unmixing was performed in real time during image capture. All microscopy  
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Figure 5. Spectral unmixing microscopy. Immunocytochemistry image of axon 
initial segments labelled with ankG antibody (red lines) and background 
autofluorescence emanating from lipofuscin pigment (green), shown prior to 
spectral unmixing (A). Channels are then separated by spectral unmixing to 
remove unwanted background autofluorescence (C) from the desired image, 
visualizing the AIS (B). 
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was performed at the Virginia Commonwealth University Department of Anatomy 
and Neurobiology Microscopy Facility.  
 
Quantitative Image analysis: 
The mouse monoclonal antibody directed against the cytoskeletal scaffolding 
protein ankyrinG was used to visualize the axon initial segments (AIS). AIS 
quantification was performed by counting the number and measuring the length of 
the AIS using the ImageJ software (U. S. National Institutes of Health, Bethesda, MD).  
The maximum intensity projection images were opened in ImageJ and the AISs were 
manually traced, using the trace tool. Pixels were the units of trace length measured 
by ImageJ. As each FOV represented 215µm x 215µm of tissue, and measured 1908 
pixels x 1908 pixels, 1µm tissue = 8.9 pixels of the image. Red lines of > 5 µm (i.e. > 
45 pixels) were considered AISs and were traced. Punctate labeling of < 5 µm (i.e. < 
45 pixels) was considered to be nodes of Ranvier and were not traced, as it has been 
shown that nodes of Ranvier are less than 3 µm long (Dupree et al., 1998). The 
lengths of the AISs, were logged using the ‘measure’ key. To eliminate AISs that 
extended beyond the boundaries of the captured FOV, which would result in an 
artificial shortening of the segment, initial segments touching any of the six edges of 
the collected z-stack image were excluded from analysis. Data for both AIS length 
and number were averaged per sample and a single average for length and for 
number was used for statistical analysis. To compare the number of AISs, the data 
are represented as a percent of non-MS (% non-MS ± SEM). The data were 
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determined to be not normally distributed and thus an unpaired t-test with Welch’s 
correction was performed. To compare AIS length, the average length of the AISs in 
microns is presented as mean ± SEM. AIS lengths were compared and tabulated in a 
length distribution graph. Images collected using other antibodies (Nfasc, CD45, 
MBP, CNP, IBA-1, HLA DR, CD 45, CD 68) were saved as maximum intensity 
projections and were surveyed and qualitatively assessed using microscopy and 
ImageJ.  All graphing and statistical analyses were performed using GraphPad Prism 
version 6.03 for Windows (GraphPad Software, San Diego, CA USA). 
 
Western Blot Analysis 
Tissue processing: 
Samples taken for western blot processing were placed in a 30ml Dounce glass 
homogenization tube and placed on ice. Lysis buffer (Schafer et al, 2009) (0.32M 
sucrose + 5mM sodium phosphate monobasic + 10mM EDTA + 0.1% SDS) and 10 
µl/ml of the protease inhibitor cocktail  (Sigma-Aldrich; P8340; St. Louis, MO)) was 
added and each sample was homogenized using a Glas-Col® motorized metal 
handled pestle tissue homogenizer (Glas-Col® Terre Haute, IN) at a motor speed of 
60 for ten strokes (1 stroke defined as one full motion of the pestle moving from the 
top of the Eppendorf tube, to the bottom and back to the top). The homogenate was 
then centrifuged at 600G  and 4°C for 10 minutes in a tabletop Eppendorf Centrifuge 
5402 (Eppendorf North America, Hauppauge, NY). The supernatants were collected 
and stored at -20°C.  
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Protein assay: 
A protein assay was performed to determine the protein concentrations of the 
homogenized samples facilitating equivalent protein loading onto the gel. Bovine 
serum albumin (BSA) standards were prepared using serial dilutions of BSA stock 
with PBS, as per the Micro BCA Kit protocol (Thermo Scientific, Rockford, IL; 
Thermo#23235). 25 µl of BSA standards and 25 µl of 1:10 diluted MS and non-MS 
samples were added in triplicates to a 96 well plate. The BCA assay kit reagents A, B 
and C were then mixed together in a 25:24:1 ratio and 200 µl of the reagent mix was 
added to each of the occupied wells. The well plate was incubated at 37°C and 
cooled for 5 minutes before being read in a spectrophotometer. The standard curve 
was determined and used to calculate protein concentrations.  
 
Western Blot Protocol: 
Protein concentrations across samples were normalized by diluting them with 
sample buffer (Lamelli sample buffer: beta-mercaptoethanol, 20:1) to ensure 
loading of 20µg of protein per lane. The samples were boiled for 5 minutes, cooled 
on ice, centrifuged and vortexed prior to loading the gel (Criterion™ TGX™ 18 well 
precast gel 4-15%). 10µl of molecular weight marker (Bio-Rad, Hercules, CA; 
Precision Plus Protein™ Kaleidoscope™) was added to the first lane. Western blot 
apparatus (Biorad Miniprotean Tetracell; Bio-Rad, Hercules, CA) was filled with 
running buffer (0.1 Tris-Glycine + 1g sodium dodecyl sulfate (SDS) and the gels 
were run at 70V for 30 minutes to allow the protein to stack, and then at 100V for an 
additional 1 hour. The gels were then removed and rocked in cold transfer buffer 
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(10x Tris-Glycine:Methanol:DI H2O, 1:2:7) for 15 minutes. A nitrocellulose 
membrane was cut to fit the gel and rocked in cold transfer buffer for 15 minutes. 
The transfer cassette was made by sandwiching the gel and nitrocellulose 
membrane between 2 blotting papers and 2 sponges. The gel was then allowed to 
transfer in a gel box on ice at 100V for 2 hours. Following the transfer, the 
nitrocellulose membrane was washed in PBS, and incubated in blocking solution 
(3% non-fat dry milk:PBST, 1.5g:50ml) for 40 minutes. The membrane was 
incubated overnight in the primary antibody (ankyrinG; 1:2500) diluted in the 
blocking solution at 4°C. The following day, the membrane was washed in PBS 3 
times for 10 minutes each, blocked for 20 minutes, and incubated in a secondary 
antibody solution for 1.5 hours. The secondary antibody solution consisted of an 
anti-mouse antibody conjugated with horseradish peroxidase (HRP) (1:5000), and 
Strep-Tactin HRP conjugate (1:10000). After two 5-minute rinses in phosphate 
buffered saline tween (PBST) (50ml of PBS+ 250µl of 10% Tween) and four 10-
minute PBS rinses, the membrane was incubated in the chemiluminescence reagent 
(Millipore Corporation, Billerica, MA; Immobilon Western Chemiluminescent HRP 
Substrate) for 5 minutes. The membrane was then transferred to the film cassette 
and developed using a Futura 2000 K automatic x-ray film processor (Fisher 
industries, Dickinson, ND). The western blot films were qualitatively assessed on an 
x-ray viewer and scanned for documentation.   
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RESULTS 
 
The axon initial segment (AIS) is the site responsible for action potential initiation 
and modulation (Meeks et al., 2007; Rasband, 2010). Alterations in the structure of 
this domain result in the disruption of impulse generation (Schafer et al., 2009).  
Previous studies from our lab (Clark et al., in review), using the Experimental 
Autoimmune Encephalomyelitis (EAE) murine model, which replicates many of the 
inflammatory aspects of Multiple Sclerosis (MS) (DeVries et al., 2012; Secor McVoy 
et al., 2015; Dupree et al., 2015), demonstrate a reduction in AIS numbers and 
length (Clark et al. in review). Interestingly, altered AIS numbers and length 
temporally correlate with poorer clinical scores in EAE mice and imply 
compromised neuronal function. Although EAE is a model of MS, it is not an exact 
replica of the disease (DeVries et al., 2012; Secor McVoy et al., 2015; Dupree et al., 
2015). Therefore to determine whether AIS numbers and AIS lengths are altered in 
the human disease, immunocytochemistry was performed on cortical gray matter 
samples from both groups. To visualize the AISs, cortical samples were 
immunolabeled with the ankyrinG antibody. AnkyrinG is prominent component of 
the AIS and is known as the AIS master organizer (He et al., 2013; Kordeli et al., 
1995; Jenkins and Bennett, 2001; Sobotzik et al., 2009; Hedstrom et al., 2008; 
Dzhashiashvili et al., 2007; Zhou et al., 1998). Samples were counterstained with the 
marker bis benzimide to label the nuclei.  
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No difference in cell number was observed between MS and non-MS samples: 
Since neuronal pathology is a known component of the MS disease process, we 
attempted to evaluate neuronal cell loss in MS and non-MS samples. For this 
approach, we employed the neuron specific marker NeuN (Saaltink et al., 2012; 
Gómez-Nicola et al., 2013; Smolders et al., 2013). Unfortunately, NeuN did not label 
the human tissue. As an alternative approach, we used bis benzimide as an indicator 
of cell number. Bis benzimide is not specific to neurons and labels the nucleus of all 
cell types. Using this nuclear marker, we quantitatively compared total cell number 
between MS and non-MS samples.  As shown in Figure 6, no difference in the 
number of bis benzimide labeled cells was observed between MS and non-MS 
groups. Although not specific to neurons, these counts indicate that cell loss is not 
observed in the MS samples.   
 
The number of axon initial segments are not significantly reduced in MS: 
To evaluate AIS number in MS and non-MS samples, the number of ankG positive 
profiles, greater than 5um, was determined per field of view. As seen in Figure 7, 
images from MS and non-MS samples reveal AISs labeling with the ankG antibody. 
AIS counts revealed a 40% reduction in the number of AISs between the MS and 
non-MS samples. Although quantitation indicated a 40% reduction in AIS number, 
statistical analysis indicated that this reduction was not significantly different 
(Figure 8). A less stringent statistical analysis, considering each field of view to be an 
independent ‘n’ number, revealed a statistically significant reduction of AISs in MS 
by 40% (p=.001134) compared to non-MS (Figure 9) 
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Figure 6. No difference in cell numbers between MS and non-MS.  The number 
of nuclei, as stained by bis benzimide, of MS samples as a percentage of non-MS 
revealed no difference in the number of cells within MS and non-MS cortex 
samples. 
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Figure 6 
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Figure 7. Sample immunocytochemistry images representative of AIS data. 
Immunocytochemistry of Non-MS tissue (panel A) and MS tissue (panel B). 
AnkyrinG labelled Axon initial segments (AIS) are shown as red lines (white 
arrows). The bis benzimide labelled nuclear regions are shown in blue. The red 
blotches are background noise caused by lipofuscin autofluorescence.  
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Figure 7 
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Figure 8. Axon initial segment numbers in multiple sclerosis compared to 
non – multiple sclerosis cortical tissue 
AIS numbers of MS samples as a percentage of non-MS shows a ~40% reduction 
(P value = 0.1934) 
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Figure 9. Axon initial segments in multiple sclerosis compared to non-
multiple sclerosis using each field of view as an individual n number.  
AIS numbers of MS samples as a percentage of non-MS shows a ~40% reduction 
(P value = 0.001134) 
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Axon initial segment lengths not reduced in multiple sclerosis: 
As presented above, the apparent reduction in the number of AISs in MS samples 
was not statistically significant; however, changes in AIS length have also been 
reported to alter AIS function (Adachi et al., 2014; Grubb and Burrone; Kaphzan et 
al., 2011; Kuba et al., 2010,2012). For example, action potential generation 
threshold changes with change in length and position of the AIS along the axon. In 
addition, our lab has previously reported that AIS length is significantly reduced in 
EAE mice and this reduced length preceded AIS loss. Therefore, I proposed that 
altered AIS length represents an early pathology of AIS disruption and may present 
in MS tissue even in the absence of AIS loss. Therefore, I quantitatively compared 
AIS length between MS and non-MS samples. To investigate potential differences in 
AIS length between MS and non-MS tissue, we measured the lengths of the ankG 
labeled AISs in both groups. Consistent with our EAE work, we analyzed AIS average 
length and compared AISs based on groupings. Regardless comparison approach, 
statistical analysis revealed no difference in AIS length between MS and non-MS 
tissue (Figure 10). As expected, the average AIS length was between 10 and 20 um.  
 
Western Blotting to isolate Axon Initial Segment Protein AnkyrinG: 
Our AIS number findings were not significantly different according to statistical 
comparison. Although not significantly different, we observed a 40% reduction. 
Therefore, we proposed that highly variability among regions may dilute  
AIS pathology. Therefore, proposed to further investigate AIS protein integrity by 
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western blot analysis. Western blot analysis provides 2 advantages: 1. Since western 
blots required homogenized samples, this approach allows a higher throughput 
method for analyzing multiple brain samples per donor, and 2. Provides higher 
resolution of pathology, as degradative products of AIS proteins would be easy to 
visualize even with modest AIS pathology.   
Since ankG and its breakdown products have previously been identified by 
western blotting and quantified by densitometric analysis (Kordeli et al., 1995; 
Schafer et al., 2009; Phillips et al., 2010), we focused out efforts of this protein for 
our western blot analysis.  As shown in Figure 11, the western blot showed protein 
bands at the molecular weights expected to see ankyrinG, at ~480 and ~200 kDA.. 
Interestingly, these bands were observed in two non-MS samples (n=3), but were 
present in only one MS sample (n=4). Bands were found at ~75 kDA as well, where 
we would expect to find ankyrinG breakdown products (Schafer et al., 2009; Phillips 
et al., 2010).  
  
No correlation between Axon Initial Segment loss in Multiple Sclerosis and 
tissue myelination: 
Myelin has been shown to play an integral role in the maintenance of the structure 
of the Node of Ranvier (Eshed-Eisenbach and Peles, 2013; Susuki et al., 2013; 
Dupree et al., 1999). The node of Ranvier and the AIS have a highly similar ion 
channel composition and organization (Rasband, 2010; Kole et al., 2008). While this 
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Figure 10. Axon Initial Segment lengths comparable between MS and non-
MS cortical tissue 
Length distribution graph comparing AIS lengths of MS and non-MS tissue. While 
the highest number of AIS lengths ranged between 10 – 20 µm, and the lowest 
number of AIS lengths were over 30 µm, a comparison across all AIS length 
subgroups, revealed no noticeable difference in AIS length between MS and non-
MS tissue.  
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Figure 11. Western Blot analysis of Ankyrin G in MS and non-MS tissue. 
Western blot film labeled with Ankyrin G antibody revealed bands at ~480 kDa 
and ~200 kDa molecular weights, where full length isoforms of Ankyrin G are 
expected to be seen. Non-MS samples (n=3) revealed two bands while MS samples 
revealed only one (n=4). Bands seen at ~75 kDa correspond to potential Ankyrin 
G breakdown products 
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would indicate a similar vulnerability of the AIS to the state of myelination of the 
neuron, previous studies in our lab (Clark et al., in review) and others (Hamad and 
Kole, 2015), using the Cuprizone mouse model of demyelination (Mason et al., 2001; 
Matsushima and Morell, 2001; Skripuletz et al., 2008), have demonstrated that the 
AIS structure is maintained in demyelinated states. Although studies indicate that 
AIS stability is not dependent on myelination in rodents, we determined whether 
the state of myelination regulates AIS stability or AIS protein stability in human 
tissue. For this study, we employed immunocytochemistry using the cyclic 
nucleotide phosphodiesterase (CNP) antibody to label myelin in MS and non-MS 
tissue. After selecting 4 MS and 4 non-MS samples that were representative of the 
trend seen in our previous AIS quantification analysis, we triple labeled non-MS and 
MS tissue samples with CNP (myelin marker), ankyrinG (AIS marker) and 
bisbenzimide (nuclear marker), as seen in Figure 12. Qualitative analysis of the 
images confirmed our previous findings of an apparent decrease in AIS number in 
MS tissue compared to non-MS tissue. Interestingly, although the MS samples 
consistently presented fewer AISs, this reduction was independent of the extent of 
myelination. As observed in Figure 12, qualitative analysis revealed that the number 
of AISs was reduced in demyelinated plaques (Figure 12-C) or in normal appearing 
grey matter (Figure 12-B). These findings suggest that the apparent reduction in AIS 
number observed in MS does not correlate with the state of cortical myelination.  
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Figure 12. No change in AIS numbers between myelinated and demyelinated 
MS tissue. Immunocytochemistry of non-MS (A) and MS (B & C) tissue labelled 
with CNP antibody (green), a myelin marker, Ankyrin G antibody (red), an AIS 
marker, and bis benzimide (blue), a cellular nuclei marker. Non-MS tissue (A) 
showed a noticeably higher number of AIS compared to all MS tissue. Myelinated 
MS tissue (B) when qualitatively compared with demyelinated MS tissue (C), 
showed no observable difference in AIS number, indicating that the lowered AIS 
counts were not related to the state of myelination of the tissue. Bis benzimide 
staining once again confirmed a consistent number of cells across all tissue 
samples. 
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DISCUSSION 
 
 
The goal of this study was to investigate axon initial segment (AIS) pathology in 
multiple sclerosis (MS). Data gathered from immunocytochemistry and, to a lesser 
extent, western blotting has demonstrated that the proteins clustering in the axon 
initial segment may be compromised in multiple sclerosis. Although the number of 
AISs was reduced by ~40% in the MS tissue as compared to non-MS tissue, this 
apparent reduction was not significantly different based on statistical analysis. 
Consistent with the apparent reduction in AIS number, the western blot findings 
also suggest a loss of AIS proteins. Quantitation of AIS lengths remained unchanged. 
Contrary to what we know about the node of Ranvier’s susceptibility to 
demyelination (Dupree et al., 1999; Dupree et al., 2004; Marcus et al., 2006; 
Pomicter et al., 2010, Dugandz ija-Novaković et al. 1995; Salzer et al., 1997; Rasband 
et al., 1998; Rasband et al., 1999; Tait et al., 2000; Bhat et al., 2001), no correlation 
between the reduction of AISs and the state of myelination of cortical MS tissue was 
observed.  
 
Axon initial segment integrity and Multiple Sclerosis : 
Axonal pathology is a hallmark feature of multiple sclerosis, as first described by 
Charcot (reviewed by Kornek and Lassmann, 1999).  Axonal damage has been 
shown to be intimately responsible for many of the characteristic signs and 
 63 
symptoms of MS, and is proposed as the cause of the progressive neurological 
decline observed in the later stages of the disease (Trapp and Dutta, 2011; Trapp 
and Nave, 2008; Haines et al., 2011). Axonal damage, specifically axonal transection, 
is abundantly observed in both active and chronic cortical lesions in MS, bearing a 
correlation to both inflammation and demyelination (Ferguson et al., 1997; Trapp et 
al., 1998). The integrity of axonal domains such as the node of Ranvier (NoR) and 
the axon initial segment (AIS) are imperative to maintaining proper axonal 
structure and function (Bhat et al, 2001; Buttermore et al., 2013; Chang and 
Rasband., 2013).  It has been shown by our lab, our collaborators and others that the 
NoR is compromised in multiple sclerosis and its models (Bhat et al., 2001; Howell 
et al., 2006; Ishibashi et al., 2002; Pillai et al., 2009; Rasband et al., 1999; Rosenbluth 
et al., 2003, 2014; Suzuki et al., 2004; Thaxton et al., 2011; Dupree et al., 2004). The 
NoR and the AIS also have a highly similar protein, and specifically ion channel 
compositions (Buffington and Rasband, 2011), implying a potentially similar 
susceptibility of AIS integrity under similar circumstances. Hence, we were 
interested in investigating the stability of the AIS in multiple sclerosis.  
 
AIS numbers: 
Immunocytochemistry of MS and non-MS tissue, labeled AISs and showed a 
dramatic decrease of AISs (>40%) in MS tissue, compared to non-MS tissue. While 
these findings are not statistically significant, we think they are of considerable 
value, as they follow the trend seen in our background studies using murine models 
of MS. There are a variety of reasons why statistical significance was difficult to 
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achieve with this study. It is well known that the use of post mortem human tissue 
in biomedical research is challenging due to several methodological problems. The 
genetic variability and epigenetic modification of the human genome, make human 
tissue much more inconsistent than animal tissue in research (Bennett, 2010). This 
is accentuated by other variables such as age, sex, comorbidities, cause of death, and 
time till harvest etc., all of which could not be controlled for in this study.  
Furthermore, the tissue we had access to for this study was poorly 
characterized topographically. Information regarding specific cortical layer, cortical 
location and orientation was not available. Additionally, we have determined, via a 
post-hoc power of analysis calculation, that the study is underpowered substantially 
limiting our ability to observe a significant difference between groups. The power of 
analysis calculation revealed that using samples of similar variability, we would 
need a total of 68 samples in both MS and non-MS groups to achieve statistical 
significance in this study. Unfortunately, additional human samples were not 
available at the time of the study.  Recently, we have obtained additional samples 
from the Netherlands Brain Bank. These samples are well characterized with regard 
to age at death, gender, age at disease diagnosis, type of disease, clinical history, post 
mortem harvest time and brain cortical region. Preliminary observations from this 
new cohort of samples using similar experimental techniques reveals a similar trend 
as presented in this study  
To strengthen our immunocytochemistry results, we conducted western blot 
analyses of human MS and non-MS tissue employing antibodies directed against 
ankyrinG. Kordeli et al. (1995) originally found two isoforms of full-length ankyrinG 
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in the AIS of human cortical tissue, at 480 and 270 kDA. A study performed by 
Schafer et al. (2009) demonstrated that the calcium-dependent cysteine protease, 
calpain, mediated AIS breakdown in a stroke model. These authors reported full-
length isoforms of ankyrinG and their breakdown products at ~95 and 72 kDa. 
Phillips et al. (2010) while investigating proteolysis in a diffuse brain injury model, 
showed full length ankyrinG bands at 212 and 220 kDA with a breakdown product 
at 75 kDA. Together these studies provide the feasibility of the western blot 
approach to quantify ankyrinG degradation. Our initial experiments to isolate 
ankyrinG were inconclusive due to the use of an ankyrinG antibody that was later 
found to be ineffective at labeling the protein on western blots. While a working 
ankyrinG antibody was eventually acquired, the quantity was insufficient to 
effectively optimize the western blot experimental conditions to provide 
quantifiable results. However, preliminary findings using the human tissue revealed 
protein bands at the molecular weights expected for ankyrinG: 2 bands with 
apparent molecular weights of  ~480 and ~200 kDA. Furthermore, these bands 
were seen in two out of three non-MS samples while only one of four MS samples 
revealed full length banding patterns suggesting that loss of ankyrinG in the MS 
samples compared to the non-MS samples.  Bands were found at ~75 kDA as well, 
where we would expect to find ankyrinG breakdown products. While highly 
preliminary, these data augment the immunocytochemistry results indicating a 
breakdown of ankyrinG in the MS samples.  
An important caveat to these findings, however, is that ankyrinG is not 
limited to AIS clustering. AnkyrinG also clusters in the node of Ranvier. Therefore, it 
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cannot be definitively concluded that ankyrinG breakdown products observed on 
the western blots results from AIS breakdown.  
 
AIS lengths: 
The AIS is the site of action potential generation and modulation. The AIS is a highly 
plastic domain, allowing it to regulate nerve excitability via alterations in its length 
and ion channel density (Yoshimura and Rasband, 2014; Kole and Stuart., 2012; 
Bender and Trussell, 2012; Kuba., 2012; Ogawa and Rasband., 2008). Previous 
studies done by our lab using a mouse model of MS, known as Experimental 
Autoimmune Encephalomyelitis (EAE), have demonstrated changes in AIS length in 
both acute and chronic disease time points (Clark et at., [in review]). In the EAE 
experiments, AIS lengths measured from mice, taken at the early time point (3 days 
post peak clinical symptoms) showed significant shortening of AISs in the EAE 
tissue, compared to the naive controls, despite no significant reduction in AIS 
numbers. However, AIS lengths measured from mice, taken at the late time point (9 
days post peak clinical symptoms) showed a much less dramatic shortening of AISs, 
despite showing a significant reduction in AIS numbers. One possible explanation 
for these findings is that the active inflammatory disease process targets the AIS 
structure and shortens it over time, leading to its eventual complete disruption. In 
acute inflammation, AIS are undergoing active degradation and shortening, but are 
still not lost. As the disease progresses, these AIS are completely lost. We postulate 
that there is a subfraction of AISs that are resistant to this inflammatory process, 
accounting for the remaining AISs see in the counts. It would follow that the lengths 
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of the remaining AISs would be unaltered, by nature of their resistance to 
inflammatory disruption.  
We were interested in investigating changes in AIS dimensions in human MS tissue, 
and performed a quantitative analysis of AIS lengths in MS and non-MS tissue. 
Statistical analysis of our data showed no change in AIS length between the two 
groups.  As we did not see a statistically significant reduction in the number of AISs 
between MS and non-MS tissue, we would not expect to see a significant change in 
AIS lengths between the two groups. Another possible explanation for the lack of 
alteration to AIS lengths despite seeing a dramatic reduction of AIS numbers in MS 
samples is that the remaining AISs found in the MS tissue are resistant to disruption 
by pathological processes. This is especially accurate since post mortem human 
samples bear a higher resemblance to late stage EAE than to early stage EAE, when 
comparing pathogenesis timelines.  While the mechanisms surrounding AIS 
disruption and shortening in these scenarios are not fully understood, we believe 
that our findings with the human tissue and murine EAE studies warrant further 
investigation in this area.   
 
AIS integrity is not related to demyelination: 
The myelin sheath, produced by the oligodendrocytes in the CNS, envelops the axon 
and plays a vital role in neuronal functioning. Disruption of the myelin sheath 
results in disruption of axonal integrity. It has been shown by our lab (Dupree et al., 
1999; Dupree et al., 2004; Marcus et al., 2006; Pomicter et al., 2010), and others 
(Kuba and Susuki., 2015; Rasband and Chang., 2013; Rasband et al., 1999; Tait et al., 
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2000; Bhat et al., 2001), that the establishment and maintenance of the node of 
Ranvier is highly dependent on the presence of myelin.  However, despite the 
compositional and structural similarities between the NoR and the AIS, studies 
show that the establishment of the AIS is not dependent on myelin (Kuba and 
Susuki., 2015; Rasband and Chang., 2013; Buttermore et al., 2013). Previous studies 
done in our lab using the Cuprizone model (a demyelinating/remyelinating murine 
model) have shown no change in AIS integrity in demyelinated mouse cortical tissue 
(Clark et al., [in review]). Furthermore, studies performed by our lab using the EAE 
model (a murine model exhibiting cortical inflammation absent any cortical 
demyelination), showed that AISs are lost in myelinated cortical tissue. These 
findings imply that the AIS structure is not dependent on myelin (Clark et al., [in 
review]).  
To determine if this trend is observed in human multiple sclerosis, we 
attempted to investigate the relationship between AISs and myelin in human MS 
tissue. Initial attempts to immunolabel the tissue using the antibodies directed 
against Myelin Basic Protein (MBP) and Myelin Oligodendrocyte Glycoprotein 
(MOG) were unsuccessful, showing little to no specific staining, as the human tissue 
in our possession was unfixed, and the antibodies required fixed tissue to effectively 
label myelin. Post-fixing the tissue yielded no discernable change in the 
effectiveness of the immunolabelling. Experiments using the antibody 2',3'-cyclic-
nucleotide 3'-phosphodiesterase (CNP) resulted in successful labeling of myelin in 
the unfixed human tissue. Qualitative analysis of the MS and non-MS human tissue 
showed similar regions of myelination and demyelination across all samples.  
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Consistent with the idea that AIS disruption is independent of myelin loss, Figure 12 
reveals comparable myelin labeling in the MS and non-MS samples while the 
number of AISs is substantially reduced in the MS samples compared to the non-MS 
samples. This suggests that AIS loss occurred in the absence of demyelination. 
Multiple sclerosis, has for decades, been considered a primarily a demyelinating and 
inflammatory disease, with subsequent axonal pathology. These findings, correlate 
with our background studies, and are extremely exciting as they suggest that axonal 
pathology is a primary event in MS, showing a disruption in axonal protein domain 
organization, independent of demyelination.  
 
In conclusion, while we did not show a statistically significant reduction of axon 
initial segments in multiple sclerosis, our results highlight a trend, which 
demonstrates the AISs may be disrupted in MS. We show that axonal pathology is a 
primary event in MS, as AIS integrity is not related to demyelination. These findings, 
while preliminary, are highly exciting as they enhance our understanding of what 
was once considered a prototype demyelinating disease.  
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